NDC 86136-017 - Nobatol
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 86136-017
- Package NDCs from labels
- 86136-017-10, 86136-017-50
- Manufacturer
- MWI/VetOne
- Effective date
- 2023-06-08
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Nobatol - MWI/VetOne | MWI/VetOne | 2023-06-08 | PRESCRIPTION ANIMAL DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| PHENOBARBITAL | PHENOBARBITAL | QUAGEN PHARMACEUTICALS LLC | 81930c69-d073-402a-9089-ae891bfddc25 | 2023-02-16 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Proficient Rx LP | 47b5e7d0-f031-4f6c-a496-c92f9f972f53 | 2023-02-01 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Proficient Rx LP | 6cf88fef-0c82-4d5d-85e8-5896ac013165 | 2023-02-01 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE | Ingenus Pharmaceuticals, LLC | 33bf2df5-bc53-4d57-a9e7-41f3fc0a03f0 | 2023-01-12 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE AND SCOPOLAMINE HYDROBROMIDE | Ingenus Pharmaceuticals, LLC | 0dd71f55-e009-48dd-809d-5f651f7521de | 2023-01-10 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Proficient Rx LP | 8fd2647b-6c3a-4b4c-a93b-304be364baf3 | 2022-08-01 | Warnings, Adverse reactions | YQE403BP4D |
| Donnatal | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE | VistaPharm, LLC | 11a48ba9-576b-4e8c-9536-6e83636d6930 | 2022-07-07 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | WINDER LABORATORIES, LLC | 1805bc08-e870-4373-b290-bed1eed87df6 | 2022-05-31 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Strides Pharma Science Limited | b3ed0ef0-41de-46b1-af5f-4b940e74921b | 2022-04-06 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Pharmaceutical Associates, Inc. | 037c7532-7688-44fd-8c76-d25e8adf5fb5 | 2022-01-05 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Rising Pharma Holdings, Inc. | fe874f8a-4b56-4d2b-abf5-8742e2633a3b | 2020-09-15 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Rising Pharma Holdings, Inc. | 9abc9dc4-1a62-480d-a0a9-fad16c154eae | 2020-07-01 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Rising Pharma Holdings, Inc. | e81ffc2f-9aa0-4b68-9d42-63d23dc30824 | 2020-07-01 | Warnings, Adverse reactions | YQE403BP4D |
| Phenohytro | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE | Winder Laboratories, LLC | 27c8baac-f8ce-46d8-8a0f-ff769dd408d9 | 2019-12-27 | Warnings, Adverse reactions | YQE403BP4D |
| Phenobarbital | PHENOBARBITAL | Proficient Rx LP | e1756186-6b8c-4965-bfa7-9d5fad3421ab | 2019-11-01 | Warnings, Adverse reactions | YQE403BP4D |
| Phenohytro | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, AND SCOPOLAMINE HYDROBROMIDE | Winder Laboratories LLC | 29be31ef-108e-4b45-9ecc-b6d671da2826 | 2019-10-04 | Warnings, Adverse reactions | YQE403BP4D |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.